LANCET, cilt.368, sa.9541, ss.1096-1105, 2006 (SCI-Expanded)
Background Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion. The aim of this study was to assess prospectively the drugs ability to prevent type 2 diabetes in individuals at high risk of developing the condition.